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Abstract: Osteopontin has been reported to stimulate cell adhesion, migration and specific signalling functions. Its over-
expression has been found in melanoma, breast, lung, colorectal, stomach and ovarian cancer. However, its overexpres-
sion and role in human breast cancer remains to be elucidated. In this study, invasive breast tumours from 129 patients 
were examined by immunohistochemistry in order to assess osteopontin association with several molecular tumour mark-
ers. Additionally, its relationship with proliferation and angiogenesis was determined. Ultimately, other tumour variables 
such as histological grade, tumour size and nodal status were also assessed. Results achieved showed that no statistical 
significant association exists between osteopontin expression and major clinicopathological parameters or angiogenesis, 
except for the number of lymph nodes involved. However, a correlation with some molecular markers was observed, 
namely with P-Cadherin, EGFR, cytokeratin 14 and vimentin. Additionally, higher proliferation rates were found for the 
tumours expressing osteopontin. Although several studies refer osteopontin as a potential breast cancer biomarker, it is 
still not clear if it can provide important diagnosis information, evaluate treatment effects or assess the potential for metas-
tatic disease in patients. 
Keywords: Osteopontin, tumour stroma, invasive breast cancer. 
INTRODUCTION 
 Cancer biomarkers that allow the anticipation of the out-
lines of disease have been an emerging issue and there is a 
growing need for additional reliable molecular markers [1]. 
Osteopontin (OPN) is a phosphorylated glycoprotein found 
in all body fluids, extracellular matrix components, and pro-
teinaceous matrix of mineralized tissues [2-4]. This protein 
was found to be overexpressed in tumours and serum of 
women with ovarian cancer, and was correlated with pro-
gression [5, 6]. Furthermore, OPN has been detected in ap-
proximately 90% of primary breast carcinomas [7, 8], and 
recent studies demonstrated that its overexpression is also 
related with breast cancer evolution and metastasis [2, 9]; 
therefore there is a potential utility of OPN in monitoring 
disease status in breast cancer patients [10]. 
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 In human tissues, OPN has been found to be produced by 
epithelial cells of the gastrointestinal, urinary and reproduc-
tive tracts, the gallbladder, pancreas, lung bronchi, lactating 
breast, salivary glands and sweat ducts [11]. OPN was local-
ized to the luminal surfaces in these sites, and also in human 
secretions including blood, milk and urine [10, 12]. Overall 
these findings suggested that OPN may have a protective 
role in interactions between epithelial surfaces and the exter-
nal environment. Nevertheless, several studies have de-
scribed a link between OPN and cancer in the past years [9, 
10, 13, 14]. Presently, it is fully accepted that OPN ex-
pressed by tumour cells alters their malignant properties, 
specifically by affecting their ability to grow, invade and 
metastasize. However, as OPN is known to be expressed in 
both normal and malignant tissues, an elucidation on its sig-
nificance in human cancer is required. 
 The association of OPN with breast tumour progression 
was studied by Tuck and co-workers [15] using samples 
from a patient who had bilateral mammary carcinomas of 
similar histology and later developed metastatic recurrence. 
Their findings suggest that OPN, both in tumour cells and in  
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plasma, may be a marker for tumour aggressiveness in breast 
cancer, and elevated levels in a primary tumour may predict 
the future development of metastasis. Furthermore, the same 
group studied the expression of OPN mRNA and protein in 
the tumours of 154 women with lymph node negative (LNN) 
breast cancer [16]. Results gathered in this study support the 
idea that OPN levels within tumour cells may be a useful 
predictor of patient outcome in breast cancer, and also that 
OPN may play a functional role in tumour progression and 
aggressiveness. A correlation between OPN expression and 
an increased invasiveness or metastatic potential has also 
been reported in other human tumours, such as melanoma, 
breast, lung, colorectal, stomach and ovarian cancer [2, 4, 10, 
17]. 
 Some studies have also reported an implicated OPN in 
angiogenesis, nevertheless many of the results remain cir-
cumstantial and further clarification on the details of this 
possible role is required [18, 19]. The association of OPN to 
this process is a consequence of its ability to bind the v3 
integrin, which in turn is a marker of angiogenesis and ex-
pressed by neovascular endothelial cells [19]. 
 Recently, Finak and co-workers [20] reported the pres-
ence of OPN in the breast tumour stroma associated with a 
poor outcome cluster of genes linked to angiogenic, hypoxic 
and tumour-associated macrophage responses. Under normal 
physiological conditions, stroma serves as an important bar-
rier to epithelial cell transformation; the interplay between 
epithelial cells and the microenvironment maintains epithe-
lial polarity and modulates growth inhibition [21]. However, 
the stromal compartment undergoes changes in response to 
emerging epithelial lesions and can have a key role in cancer 
initiation and progression [21, 22]. These changes may in-
clude the recruitment of immune endothelial cells providing 
growth and matrix remodelling factors, as well as a new 
blood supply promoting tumour growth and metastasis [21-
23]. 
 
 The aim of the present study was to examine by immu-
nohistochemistry (IHC) on tissue microarrays (TMAs), the 
OPN expression in invasive tumour stromas from 129 pa-
tients in order to assess its association with several molecular 
tumour markers (ER (estrogen receptor), HER2 (human epi-
dermal receptor 2), CK5 (cytokeratin 5), CK14 (cytokeratin 
14), CK8/18 (cytokeratin 8/18), p63, P-CD (P-cadherin), 
EGFR (epidermal growth factor receptor), PgR (progester-
one), VIM (vimentin)). Additionally, the relationship of 
OPN with proliferation (Ki67) and angiogenesis (CD105 - 
endoglin) was determined. Ultimately, other tumour vari-
ables such as histological grade, tumour size and nodal status 
were also assessed. 
MATERIALS AND METHODOLOGY 
Patients’ Selection 
 One hundred and twenty nine tumour samples were ob-
tained from patients treated at the Federal University of 
Santa Catarina, Florianopolis-SC, Brazil and kindly given to 
us for this work. Of these, 22 tumours presented clinical fea-
tures of familial breast cancer according to the Breast Cancer 
Linkage Consortium [24, 25], 96 tumours were from patients 
without any clinical familial feature (sporadic) and 11 tu-
mours had no clinical data available to determine if they 
have clinical features of familial breast cancer. 
Tissue Microarray Construction 
 Representative areas of the invasive breast carcinomas 
were carefully selected on hematoxylin and eosin (H & E) – 
stained sections and marked on the correspondent individual 
paraffin blocks. Two tissue cores (2 mm in diameter) were 
obtained from each selected specimen and precisely depos-
ited into a recipient paraffin block using TMA workstation 
(TMA builder ab1802, Abcam, Cambridge, UK). Eighteen 
TMA blocks were constructed, each containing 24 tissue 
cores, arranged in a 4x6 sector. In each TMA block, nonneo-
plastic breast and testicular tissue cores were also included as 
controls and TMA guide, respectively. After construction, 2 
Table 1. Antibodies Used in the Immunohistochemistry Study 
 
Molecular Marker Antibody Origin Clone Dilution Antigenic Retrieval (min) 
ER Rmab Neomarkers, USA SP1 1:150 30 
HER2 Rmab Neomarkers, USA SP3 1:80 30 
CK5 Mmab Neomarkers, USA XM26 1:50 30 
P63 Mmab Neomarkers, USA 4A4 1:150 30 
P-CD Mmab BD Transduction, KY, USA 56 1:50 30 
EGFR Mmab Zymed, USA 31G7 1:100 30 
CK14 Mmab Novocastra, UK LL002 1:400 30 
CK8/18 Mmab Zymed, USA UCD/PR-10.11 1:50 40 
PgR Rmab Neomarkers, USA SP2 1:300 30 
VIM Mmab DakoCytomation V9 1:150 30 
Ki67 Rmab Neomarkers, USA SP6 1:300 30 
OPN Mmab Santa Cruz, USA AKm2A1 1:500 30 
CD105 Mmab Novocastra, UK 4G11 1:50 30 
Mmab – mouse monoclonal antibody; Rmab – rabbit monoclonal antibody. 
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μm tissue sections were cut and adhered to Superfrost Plus 
glass slides. An H & E – stained section from each block was 
reviewed to confirm the presence of morphological representa-
tive areas of the initially identified lesions. All the markers 
were assayed in TMAs, except for CD105 (endoglin) that was 
assayed using whole tissue sections of each case. 
Immunohistochemistry 
 Immunohistochemical staining for ER, HER2, CK8/18, 
VIM, CK5, p63, OPN, LF and CD105 was performed using 
the streptavidin-biotin-peroxidase technique (LabVision Cor-
poration, Fremont, CA, USA) in each set of 18 glass slides 
comprising the TMAs, whereas P-CD, CK14, EGFR, Ki67 
and PgR used the HRP labelled polymer (DakoCytomation, 
Carpinteria, CA, USA). 
 Antigen unmasking for p63, ER, HER2, OPN, VIM, PgR, 
Ki67 and CD105 was carried out using a dilution of 1:100 from 
a commercially available solution of citrate buffer, pH=6.0 
(Vector Laboratories, Burlingame, CA, USA) at 98°C, whereas 
a dilution of 1:10 from tris-ethylenedi-aminetetraacetic (EDTA) 
solution with pH=9.0 (DakoCytomation) was used for CK5, P-
CD and CK14. 
 Epitope retrieval for EGFR was performed by proteolytic 
enzyme digestion (pepsin A, 4 g/l; Sigma-Aldrich, Germany) 
at 37°C, and for CK8/18 a solution of PT Module Buffer 
(LabVision) was used. 
 The antigen retrieval times, antibodies, dilutions and sup-
pliers are listed in Table 1. After washes in a phosphate buffer 
solution (PBS), endogenous peroxidase activity was blocked 
by incubation of the slides in a 3% hydrogen peroxide (Pan-
reac, Spain) in methanol (Sigma-Aldrich). The slides were 
incubated with a blocking serum (LabVision) for 15 min and 
then incubated with the specific antibody. 
 Primary antibody incubation was performed for 30 min-
utes at room temperature (ER, HER2, PgR, CK8/18 and 
VIM), for 1h at room temperature (P-CD, p63, CK5, EGFR, 
CK14, Ki67 and OPN) or overnight at 4ºC (CD105). After 
washes, the slides were incubated with biotinylated secondary 
antibody, followed by streptavidin-conjugated peroxidase 
(LabVision). Diaminobenzidine (DAB) was used as a chro-
mogen (DakoCytomation). 
 For P-CD, CK14, EGFR, Ki67 and PgR staining, the sec-
ondary antibody was associated with HRP labelled polymer 
(DakoCytomation) and immediately revealed with DAB. Tis-
sues were then counterstained with Mayer’s hematoxylin, de-
hydrated and coverslipped using a permanent mounting solu-
tion (Zymed, San Francisco, CA, USA). 
 Positive controls were included in each run in order to 
guarantee the reliability of the assays. Nonneoplastic breast 
tissue cores, as well as normal breast surrounding the neoplas-
tic cells, were considered internal controls for most of the an-
tibodies tested: p63, CK5, CK14, P-CD, EGFR (myoepithelial 
cells); ER, PgR, CK8/18 (epithelial cells); VIM (stromal 
cells). The evaluation of immunohistochemistry results was 
done by two pathologists (F. Schmitt and F. Milanezi), as fol-
lows: P-CD was considered positive whenever more than 10% 
of the neoplastic cells showed membrane staining, usually 
associated to cytoplasmic staining [26]; similarly, we adopted 
the same cutoff value for nuclear ER and PgR reactivity.  
 
CK5, CK14, OPN and VIM were considered positive when-
ever any cytoplasmic staining was observed in the neoplastic 
cells. OPN expression was evaluated also in the stroma com-
ponent of the tumour [15, 16, 20, 27-31]. p63 was considered 
positive whenever nuclear staining was seen, and CK8/18 was 
considered positive whenever cytoplasmic and/or membrane 
staining was observed. HER2 expression was evaluated ac-
cording to the DakoCytomation HercepTest scoring system:  
0 - no staining or membrane staining in fewer than 10% of 
tumour cells; 1+ - faint, barely perceptible membrane staining 
in more than 10% of tumour cells, the cells are stained only in 
part of the membrane; 2+ - weak to moderate complete mem-
brane staining observed in more than 10% of tumour cells; and 
3+ - strong, complete membrane staining in more than 10% of 
tumour cells. Cases were considered positive (overexpression) 
for HER2 when the immunostaining was classified as 3+. 
EGFR staining was also classified according to the Her-
cepTest scoring system, but breast carcinomas were consid-
ered positive whenever the immunostaining was 2+ or 3+. 
Three categories were defined for Ki67: <10%, 10-20% and 
>20% of stained nuclei. For CD105 evaluation, tumour mi-
crovessel density was determined by the average number of 
new vessels, counted with an amplification of 200X, in 3 dif-
ferent hotspots. 
 Finally, according to several authors [32, 33]
 
we classified 
each tumour in a practical way based on its ER and HER2 
expression. 
Statistical Analysis 
 The 2 contingency test was used for categorical variables 
to determine differences between the phenotypes. A p value of 
less than 0.05 was considered to reflect a significant associa-
tion. The angiogenesis data were compared using the non pa-
rametric Mann-Whitney test at a confidence level of 95%. 
Data processing and statistical analysis were performed using 
Microsoft Office Excel 2007 (Microsoft Corp, Redmond, 
WA) and SPSS 16.0 software (SPSS Inc., Chicago, Illinois, 
USA). 
RESULTS 
Immunohistochemistry Profiles in Breast Tumours 
 We performed IHC for ER, HER2, EGFR, PgR, CK5, 
P63, P-CD, CK14, CK8/18, VIM, Ki67 and OPN. The CD105 
assay was performed using whole tissue sections. The results 
obtained are gathered in Table 2 and Fig. (1). In our series we 
observed that 61.2% of breast carcinomas were ER-positive, 
and 22.7% were HER2-positive. Less than 34.4% of the tu-
mours analyzed presented expression of a basal marker (P-
CD, p63, CK14 and CK5). Table 3 summarizes the clustering 
of a total of 129 cases immunohistochemically interpretable to 
allow sample characterization into one of five groups (Lumi-
nal A, luminal B, basal, HER2 overexpressed or unclassified) 
as described elsewhere [32]. Based on this classification, we 
observed that basal-like comprised 16.3% of all tumours, 
whereas luminal A and B comprised 54.3% and 5.4%, respec-
tively. HER2-overexpressing tumours represented 17.1% of 
the series, and null phenotype/unclassified, 7.0% (Table 3). As 
expected the protein expression profiles clearly differed in 
luminal A, luminal B, basal, and HER2-overexpressing tu-
mours concerning P-CD, CK5, EGFR, CK14, CK8/18, PgR, 
VIM, Ki67,  and CD105  (data not shown).  Furthermore, we  
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Table 2. Results of Immunohistochemistry Staining on Tissue 
Microarrays 
 
Molecular  
Marker 
Interpretable  
Cores (n) 
Positive  
Staining (%) 
Negative  
Staining (%) 
ER 129 61.2 38.8 
HER2 128 22.7 77.3 
CK5 129 25.6 74.4 
P63 129 6.2 93.8 
P-CD 128 34.4 65.6 
EGFR 128 2.3 97.7 
CK14 128 6.3 93.8 
CK8/18 127 100.0 0.0 
PgR 129 35.7 64.3 
Vimentin 129 13.2 86.8 
OPN 129 43.4 56.6 
 
Table 3. Frequencies of Immunohistochemistry Defined Sub-
types of Breast Carcinomas in 129 Invasive Tu-
mours for the Tested Markers Using Tissue Mi-
croarrays 
 
Subtype ER HER2 Frequency [n*, (%)] 
Luminal A + - 70 (54.3) 
Luminal B + + 7 (5.4) 
HER2-overexpressed - + 22 (17.1) 
Basal - - 21 (16.3) 
Unclassified** - - 9 (7.0) 
* Interpretable cores. 
** Basal markers, such as P-CD, p63, CK14 and CK5, are also negative. 
 
examined the relationship between OPN expression in tu-
mour stroma and the other molecular markers tested, as well 
as with other tumour variables such as size, nodal status and 
histological grade. From a total of 129 cases immunohisto-
chemically interpretable, we found that 43.4% of the cases 
showed a positive staining for OPN in the tumour stroma 
(Table 2). Among the OPN positive cases, the distribution of 
cancer subtypes found was 50.0% Luminal A, 5.4% Luminal 
B, 23.2% Basal and 17.9% HER2-overexpressing tumours 
(p=0.304) (Table 4). Moreover, regarding cancer subtype, it 
can be seen from Table 4 that cases negative for OPN 
showed higher percentages of Luminal A (57.5%) tumours 
as compared with the positive ones. Significant statistically 
differences between the two groups (OPN positive and OPN 
negative) were observed for few of the studied molecular 
markers, such as P-CD (p=0.032), EGFR (p=0.077), CK14 
(p=0.066) and VIM (p=0.069). OPN positive tumours pre-
sented mainly histological grade I and II (30.4% and 43.5%, 
respectively) and demonstrated a higher frequency of P-CD 
and VIM expression (44.6% and 19.6%, respectively) as 
compared to OPN negative tumours (no statistical signifi-
cance was although observed, p=0.941). On the other hand, 
cases negative for OPN showed mainly histological grade II 
(46.5%) and higher frequency of cases ER-positive, PgR-
positive and P-CD-negative (64.4%, 41.1% and 73.6%,  
 
Table 4. Immunohistochemistry Profiles of OPN Staining in 
Tumour Stroma 
 
  
OPN + 
 [n*, (%)] 
OPN - 
 [n*, (%)] 
p 
Luminal A 28 (50.0) 42 (57.5) 
Luminal B 3 (5.4) 4 (5.5) 
Basal 13 (23.2) 8 (11.0) 
HER2  
overexpressed 
10 (17.9) 12 (16.4) 
Tumour  
subtype 
Unclassified 2 (3.6) 7 (9.6) 
0.304 
Grade I 14 (30.4) 22 (31.0) 
Grade II 20 (43.5) 33 (46.5) 
Histological  
grade 
Grade III 12 (26.1) 16 (22.5) 
0.941 
ER + 32 (57.1) 47 (64.4) 
ER - 24 (42.9) 26 (35.6) 
0.513 
HER2 + 13 (23.6) 16 (22.2) 
HER2 - 42 (76.4) 56 (77.8) 
1.000 
CK5 + 15 (26.8) 18 (24.7) 
CK5 - 41 (73.2) 55 (75.3) 
1.000 
P63 + 5 (8.9) 3 (4.1) 
P63 - 51 (91.1) 70 (95.9) 
0.293 
p-CD + 25 (44.6) 19 (26.4) 
p- CD - 31 (55.4) 53 (73.6) 
0.032 
EGFR + 3 (5.5) 0 (0.0) 
EGFR - 52 (94.5) 73 (100.0) 
0.077 
CK14 + 6 (10.7) 2 (2.8) 
CK14 - 50 (89.3) 70 (97.2) 
0.066 
CK8/18 + 56 (100.0) 71 (100.0) 
CK8/18 - 0 (0) 0 (0) 
1, 000 
PgR + 16 (28.6) 30 (41.1) 
PgR - 40 (71.4) 43 (58.9) 
0.194 
VIM + 11 (19.6) 6 (8.2) 
Molecular  
markers 
VIM - 45 (80.4) 67 (91.8) 
0.069 
< 10% 19 (34.5) 49 (67.1) 
10-20% 5 (9.1) 6 (8.2) 
Proliferation  
rates Ki67 
> 20% 31 (56.4) 18 (24.7) 
0.001 
T1 (<2cm) 18 (33.3) 24 (35.3) 
T2 (2-5cm) 29 (53.7) 31 (45.6) Tumour size 
T3 (>5cm) 7 (13.0) 13 (19.1) 
0.572 
Yes (86 cases) 33 (62.3) 53 (75.7) Lymph nodes  
metastases No (37 cases) 20 (37.7) 17 (24.3) 
0.117 
0 14 (42.4) 11 (20.8) 
1-3 9 (27.3) 19 (35.8) 
Number of  
lymph nodes  
involved 
>3 10 (30.3) 23 (43.4) 
0.107 
* Interpretable cores. 
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Fig. (1). Expression of proteins and H&E staining of the core represented in each marker studied by IHC on TMAs. All TMA cores represent 
neoplastic tissue with a strong staining pattern. Except for cases d2, e2, f2, i2 and l2 where it was used an original magnification of X630, for 
all the others it was used X400: (a1, a2) – (H&E, ER staining); (b1, b2) – (H&E, HER2 staining); (c1, c2) – (H&E, CK5 staining); (d1, d2) 
– (H&E, p63 staining); (e1, e2) – (H&E, P-CD staining); (f1, f2) – (H&E, EGFR staining); (g1, g2) – (H&E, CK14 staining); (h1, h2) – 
(H&E, CK8/18 staining); (i1, i2) – (H&E, PgR staining); (j1, j2) – (H&E, VIM staining); (l1, l2) – (H&E, Ki67 staining); (m1, m2) – (H&E, 
CD105 staining); (n1, n2) – (H&E, OPN stroma staining). 
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respectively). A low expression of basal markers was ob-
served for both groups (OPN positive and OPN negative). 
Microvessel density is regarded as a surrogate marker for an-
giogenesis and has been used for tumour prognosis. In this 
study, microvessel density was identified immunohistochemi-
cally using a monoclonal antibody against CD105 (endoglin) 
in invasive breast cancer tissue sections. The expression of 
CD105 in the microvessels within both groups, OPN-positive 
(mean 26 ± 9 microvessels/mm
2
; range 9-47) and OPN-
negative (mean 24 ± 10 microvessels/mm
2
; range 9-72), was 
similar and no statistical significant difference was observed 
(p=0.298). 
 Regarding the Ki67 proliferation indices (indicator of 
prognosis in breast cancer), a strong statistical difference 
(p=0.001) could be observed between OPN- positive and 
negative groups. Higher Ki67 proliferation indices (> 20%) 
were detected for the OPN-positive group (56.4%) (Table 4). 
 Regarding tumour size (Table 4), we observed that OPN-
positive cases showed higher frequencies of tumours between 
2 and 5cm (53.7%), whereas cases OPN-negative showed 
higher frequencies of T1 (smaller than 2cm) (35.3%) 
(p=0.572). Additionally, we found that the cases OPN-
negative showed a higher number of lymph nodes involved 
(>3) as compared to the cases OPN-positive (Table 4) 
(p=0.107). 
DISCUSSION 
 The purpose of this work has been to establish, using im-
munohistochemical techniques, the level of expression of the 
glycoprotein OPN in the stroma of human invasive breast car-
cinomas and its clinical significance. We have found that 
43.4% of the carcinomas are stained positively for OPN by the 
mouse monoclonal antibody to human OPN (mAB clone 
Akm2A1), which is slightly below the overall staining levels 
previously reported with other antibodies, namely with a 
monoclonal antibody mAB 53 prepared against the recombi-
nant GST-human OPN fusion protein, or with a rabbit poly-
clonal antibody to human OPN (70-80%). The mAB Akm2A1 
antibody used in this study as proven to be very specific for 
OPN, especially for endometrial carcinomas [7, 15, 16, 25, 28, 
34, 35]. As referred previously and in agreement with other 
reports [9, 10, 16, 36], the staining in specimens is not re-
stricted to carcinoma cells, because variable, often reduced 
levels are detected in normal parenchymal breast tissue and in 
some reactive fibroblast-like cells, macrophages, lymphocytes 
and blood vessels [37, 38]. Furthermore, OPN was recently 
found in the breast cancer stroma [20] associated with a poor 
outcome cluster of genes linked to angiogenic, hypoxic and 
tumour-associated macrophage responses. Contrary to previ-
ous published results [16, 29, 39], in this study no significant 
association could be observed between OPN expression and 
tumour variables such as nodal status (p=0.107) and tumour 
size (p=0.572). Nevertheless, these results are in accordance 
with those published by Kim and co-workers [28] that also 
failed to find an association of immunohistochemical staining 
for OPN and any clinicopathological parameters in 253 cases 
of breast cancer. In their study, 87% of the patients exhibited 
OPN-positive carcinomas, which is considerably higher than 
other reports. This higher proportion was found to be a conse-
quence of using a polyclonal antibody to human OPN that 
recognizes an extra Mr 45, 000 polypeptide in extracts of 
breast cancers, and therefore this number of positive cases was 
overestimated. Furthermore, Ribeiro-Silva and co-workers 
[40] also studied OPN expression in invasive breast cancers 
and couldn’t correlate it with several markers and clinicopa-
thological features, such as grading and tumour size. In addi-
tion, also no correlation between OPN expression and basal-
like phenotype was found. It is important to notice that al-
though several studies have been published recently on the 
involvement of OPN in breast cancer (and other types of can-
cer) [2, 15, 16, 20, 28, 29], it is not straightforward to compare 
the results obtained by different researchers. Some of these 
studies were performed using cell lines [2, 37], plasma [2] or 
paraffin blocks of tumours [16, 28, 29, 37]. Moreover, these 
studies focus on parameters such as disease free and patient 
survival, that were not included in our study. In addition, the 
most commonly reported markers are p53, ER and PR. There-
fore, some of the molecular markers used in our work have 
never been studied together with OPN. 
 The fact that there is no significant correlation between the 
presence of OPN and major pathological tumour variables 
associated with poor patient prognosis as lymph node metasta-
sis and tumour size, may reflect the characteristics of the tu-
mours in this group of patients (54.3% luminal-type A and 
16.3% basal-type), as well as the size of the sample. Patients 
with luminal-type A tumours have the most favourable prog-
nosis, whereas patients with basal-type tumours have worst 
prognosis [41]. Our results are in accordance with the work 
described by Rudland and co-workers [29], as they state that 
the association of OPN with worse prognosis appears to be 
independent of nodal status and other established clinical 
prognostic indicators. In our study, a minority (16.4%) of the 
tumours are classified as T3; this is a small fraction in com-
parison with other groups of patients [42]. Moreover, nodal 
status has been undertaken on only 62.3% of the tumours. 
These smaller numbers may be responsible for the less mean-
ingful associations. 
 Additionally, several molecular markers were tested for 
association with immunohistochemical staining for OPN in 
human invasive breast carcinomas, however only P-CD, 
EGFR, CK14 and VIM, showed statistical significance. 
 As in other types of carcinomas, transformation of the 
normal breast epithelium into an invasive malignancy is the 
result of multiple steps. These steps consist of transformation 
of normal to an atypical hyperplastic epithelium with a subse-
quent high risk of progression to intraductal carcinoma, fol-
lowed in some cases by invasion into the stroma [43]. A basic 
feature of normal breast histology is the maintenance of spe-
cific adhesive relationships between epithelial cells, between 
epithelial and myoepithelial cells, and between cells and the 
extracellular matrix. Disruption or deregulation of these adhe-
sive relationships causes a loss of ductal and lobular architec-
ture and accompanies neoplastic transformation. Furthermore, 
progression to malignant phenotypes involves local invasion 
and metastasis, two processes in which cell-cell and cell-
extracellular matrix adhesions are altered. The mechanism of 
OPN overexpression and its role in human breast cancer is not 
clear. Although it is generally accepted that OPN occurs in the 
carcinoma cells themselves, the relative proportion seques-
tered from host cells such as activated macrophages and/or 
lymphocytes, and that is produced in situ has varied consid-
erably [27, 36], but at least a sizeable proportion is now be-
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lieved to arise from overexpression of OPN mRNA in the car-
cinoma cells themselves [7, 16, 34, 37]. OPN interacts with a 
variety of cell surface receptors, including several integrins 
and CD44, stimulating cell adhesion, migration, and specific 
signalling functions [9, 10, 29, 38, 44, 45]. Additionally, OPN 
has been reported to play a role in tumour invasion and metas-
tasis, where adhesive interactions between tumour cells and 
extracellular matrix are critical [8]. 
 VIM is the intermediate filament protein usually restricted 
to mesenchymally derived tissue and which has been strongly 
correlated with basement membrane invasiveness in vitro by a 
variety of tumour cell lines [46]. VIM-positive cells, as a 
group, are significantly more invasive than their more epithe-
lial counterparts, and expression of VIM in epithelial tumours 
is thought to arise by a process resembling the epithelial to 
mesenchymal transition (EMT). The EMT, known to occur 
transiently when epithelial cells need to adopt a migratory and 
possibly invasive state during embryogenesis, organ develop-
ment, and wound healing, has been shown to be regulated by 
both growth factors and extracellular matrix (ECM) compo-
nents [46]. Although only of borderline significance, our re-
sults showed a positive correlation between OPN and VIM 
expression which is in accordance with the previous reports 
[46]. Moreover, it has been reported that VIM is positively 
correlated with EGFR and Ki67 [47], and in our study we also 
found a positive correlation between OPN and these markers. 
 A co-expression of P-CD and OPN was found in this 
study; however these results are distinct from the ones ob-
tained by Cheng and co-workers [48]. These researchers found 
that a dominant negative E-cadherin implied a transiently in-
crease of OPN expression, but a decreased cell-cell adhesion 
associated with altered bone matrix protein expression and a 
decreased matrix mineralization. P-CD is restricted to the ba-
sal or lower layers of stratified epithelia, suggesting that in 
addition to maintaining cellular adhesion, P-CD may have 
other functions in differentiation and cell growth, as well as 
OPN [49, 50]. Although both P-CD and OPN have been re-
ported as having an adhesive function, their role may be dif-
ferent and not necessarily correlated, thus, further work is nec-
essary in order to elucidate a possible relation between these 
proteins. 
 Additionally, some researchers found that a ligation of 
integrins by OPN leads to activation of EGFR receptor [51, 
52] via src-dependent transactivation, with resulting activation 
of downstream signalling pathways such as P13K, Ras-
MAPK, PLC and PKC, in turn activating AP-1 dependent 
uPA expression [53]. In our study, a significant association 
was found between OPN and EGFR. 
 Finally, OPN has been implied in tumour cell proliferation 
and angiogenesis [3, 18, 37, 54]. A strong tendency for higher 
proliferation rates was achieved for OPN-positive cases, 
which is in accordance with the literature. This tendency is 
probably associated with the activation of different compo-
nents of the local adhesion complex that could in turn activate 
a number of different signal transduction pathways affecting 
cellular properties such as proliferation [9, 10]. Some studies 
have reported an implicated OPN in angiogenesis, however, 
many of the results remain circumstantial and further clarifica-
tion on the details of this possible role are required. The asso-
ciation of OPN with this process is a consequence of its ability 
to bind v3 integrin, which in turn, is a marker of angiogene-
sis and is expressed by neovascular endothelial cells [3, 10, 
37, 54]. Nevertheless, in this study no significant difference 
could be observed between OPN-positive and -negative cases 
regarding angiogenesis. 
 Endoglin has been reported to be upregulated in proliferat-
ing endothelial cells and to be strongly expressed in the 
neovasculature of a wide range of solid tumours [55]. In non 
malignant adult tissue vessels, including pre-neoplastic le-
sions, endoglin expression is weaker than in tumour vessels 
and often restricted to capillaries [55]. According to Balza and 
co-workers [56], although endoglin is upregulated in tumour 
vasculature, its expression is not restricted to tumour tissues, 
and their findings shown a widespread distribution of the anti-
gen in vessels of normal adult tissues. Therefore, further de-
tailed analyses are needed in view of endoglin-specific anti-
body applications in tumour diagnosis. 
CONCLUSION 
 In sum, it remains to be determined how widespread the 
association between OPN and patient survival will prove to 
be, not only in breast but in other metastatic carcinomas. Thus 
far pilot studies on a small group of lymph node-negative 
breast cancer [16] and gastric cancer [17] patients have shown 
a positive association with patient demise and disease progres-
sion, respectively, whereas in ovarian cancers a surprising 
association with low malignant tumours has been reported 
[57]. With this work, we showed, in one group of invasive 
human breast cancer cases, that no statistical significant asso-
ciation exists between OPN expression, major clinicopa-
thological parameters and some of the commonly used mo-
lecular markers. Also, no correlation was found between OPN 
expression and angiogenesis as discussed above. Nevertheless, 
a strong tendency for higher proliferation rates was observed 
for individuals classified as OPN-positive. Therefore, although 
many studies have been recently published on OPN potential 
as a breast cancer biomarker, it is still not clear if it can pro-
vide important diagnosis information, evaluate treatment ef-
fects or assess the potential for metastatic disease in patients. 
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